---
title: 'Funding Daily Summary: What Happened on October 21, 2026'
headline: Nouscom raises €120 million to advance cancer vaccine
description: The financing will support NOUS-209. Nouscom plans to present long-term
study results in Lynch Syndrome carriers on October 25.
url: https://thebench.bio/news/funding/2026-10-21
topic: funding
date: '2026-10-21'
covers:
- '2026-10-21'
date_published: '2026-10-22T00:01:23Z'
date_modified: '2026-10-22T00:01:23Z'
tags:
- Funding
sources: 1
publisher: TheBench.Bio
---
# Funding Daily Summary: What Happened on October 21, 2026
**Nouscom raises €120 million to advance cancer vaccine**
The financing will support NOUS-209. Nouscom plans to present long-term study results in Lynch Syndrome carriers on October 25.
## Today in brief
Nouscom raised €120 million in an oversubscribed Series D to advance its lead program, NOUS-209. [1] Long-term results from a Phase Ib/II study in Lynch Syndrome carriers are due at ESMO on October 25. [1]
## Nouscom secures €120 million for NOUS-209
M Ventures and Revelation Partners led the round. Angelini Industries, the European Investment Bank and Neva SGR joined as new investors. [1] Existing investors also participated. [1]
Nouscom is studying NOUS-209 as a preventive immunotherapy for people with Lynch Syndrome, an inherited condition that raises cancer risk. [1] The company plans to present long-term Phase Ib/II results from the study in Madrid on October 25. [1]
## The day in numbers
- **€120 million**: Nouscom's Series D financing to advance NOUS-209. [1]
## Sources
1. [Preventive Cancer Vaccine Maker Nouscom Raises $135M and Presents Promising Lynch Syndrome Data ](), Inside Precision Medicine, 2026-10-21
---
TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.
[1]: